Joseph Timothy Marakovits

USPTO Granted Patents = 20 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 3)

Average Co-Inventor Count = 7.1

ph-index = 5

Forward Citations = 65(Granted Patents)

Company Filing History:

10 out of 174

Agouron Pharmaceuticals, Inc.

Biosplice Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12134625 - Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof (2024-11-05),

2. 11673881 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2023-06-13),

3. 11174244 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2021-11-16),

4. 10556885 - Isoquinolin-3-YL carboxamides and preparation and use thereof (2020-02-11),

5. 10508099 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2019-12-17),

6. 10392383 - 3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof (2019-08-27),

7. 10329309 - 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof (2019-06-25),

8. 10287267 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2019-05-14),

9. 10195185 - 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof (2019-02-05),

10. 10188634 - 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof (2019-01-29),

11. 8530652 - Pyrrolopyrazoles, potent kinase inhibitors (2013-09-10),

12. 8067591 - Pyrrolopyrazole, potent kinase inhibitors (2011-11-29),

13. 6995142 - Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis (2006-02-07),

14. 6906198 - Antipicornaviral compounds, their preparation and use (2005-06-14),

15. 6548494 - Tricyclic inhibitors of poly(ADP-ribose) polymerases (2003-04-15),

Title: Innovations and Contributions of Joseph Timothy Marakovits

Introduction: Joseph Timothy Marakovits is an esteemed inventor based in Encinitas, California. With a remarkable portfolio of 20 patents, his work primarily focuses on developing therapeutic compounds aimed at treating various diseases. His contributions to the field of medicinal chemistry have made a significant impact on both research and clinical applications.

Latest Patents: Among his latest innovations, Marakovits has developed two notable patents. The first is related to Pyrrolo[2,1-f][1,2,4]triazines, which highlights the preparation and uses of these compounds in treating diseases characterized by overexpression of DYRK1A. These disorders include cancer, Down syndrome, Alzheimer's disease, diabetes, viral infections, and osteoarthritis. The second patent pertains to Isoquinolin-3-yl carboxamides, focusing on treating various conditions linked to the Wnt pathway signaling activation. This has implications for diseases such as cancer, abnormal cellular proliferation, angiogenesis, and several neurological conditions linked to DYRK1A overexpression.

Career Highlights: Throughout his career, Marakovits has worked with influential organizations, including Agouron Pharmaceuticals, Inc. and Samumed, LLC. His roles in these companies have allowed him to contribute significantly to pharmaceutical developments and innovations within the biomedical field.

Collaborations: Marakovits has collaborated with distinguished colleagues such as Sunil Kumar KC and Chandramouli Chiruta. These partnerships have fostered a collaborative environment aimed at advancing research and addressing critical health challenges.

Conclusion: Joseph Timothy Marakovits stands out as a pioneering inventor whose innovative patents and collaborations have the potential to shape the future of drug development. His work in creating compounds aimed at treating serious medical conditions underscores the importance of innovation in improving healthcare outcomes. Through his contributions, Marakovits continues to be a valuable asset in the field of medicinal research and development.

This text is generated by artificial intelligence and may not be accurate.